Global Coagulation Factor VII Treatment Market, By Type (Inherited factor VII deficiency, Non-inherited factor VII deficiency), Treatment (Recombinant Factor VIIa, Fresh Frozen Plasma and Cryoprecipitate, Prothrombin Complex Concentrates, Antifibrinolytic Agents, Others), Diagnosis (Clotting Tests, Factor Assays, Prenatal Diagnosis, Others), Symptoms (Bleeding in soft tissues and muscles, Frequent bruising, Bleeding in the spaces of joints, Excessive bleeding from injuries or surgical wounds, Nosebleeds, Blood in urine, Bleeding gums, Heavy menstrual bleeding, Bleeding in the skull, Bleeding in the gut, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Global Coagulation Factor VII Treatment Market Analysis and Size
The rise in the prevalence of factor VII deficiency and growing healthcare expenditure are the major factors influencing the market growth rate. Furthermore, growing government funding and rising initiatives by government and private organizations to spread awareness about the disease are the factors that will expand the coagulation factor VII treatment market. Also, development of medical technology, genetic counseling and surge in the adoption rate of early screening will act as drivers and cushion the market growth rate. However, high cost of treatment and side effects associated with the treatment are the factors that will hinder the market growth. Lack of awareness will further challenge the global coagulation factor VII treatment market in the forecast period 2023-2030
Data Bridge Market Research analyses that the global coagulation factor VII treatment market is expected to undergo a CAGR of 9.80% during the forecast period 2023-2030. This indicates that the market value. “Inherited factor VII deficiency” dominates the type segment of the global coagulation factor VII treatment market owing to rising demand of the coagulation factor VII treatment products. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Coagulation Factor VII Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Inherited factor VII deficiency, Non-inherited factor VII deficiency), Treatment (Recombinant Factor VIIa, Fresh Frozen Plasma and Cryoprecipitate, Prothrombin Complex Concentrates, Antifibrinolytic Agents, Others), Diagnosis (Clotting Tests, Factor Assays, Prenatal Diagnosis, Others), Symptoms (Bleeding in soft tissues and muscles, Frequent bruising, Bleeding in the spaces of joints, Excessive bleeding from injuries or surgical wounds, Nosebleeds, Blood in urine, Bleeding gums, Heavy menstrual bleeding, Bleeding in the skull, Bleeding in the gut, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc.(U.S.), Bayer AG(Germany), Baxter(U.S.), Biogen(U.S.), Octapharma AG (Switzerland), CSL Limited (Australia), Novo Nordisk A/S(Denmark), Mylan N.V.(U.S.), Sanofi (France), Zydus Cadila(India), Aurobindo Pharma (India), Takeda Pharmaceutical Company Limited.(Japan), Akorn, Incorporated(U.S.) Xanodyne Pharmaceuticals, Inc.(U.S.), AmeriGen Life Sciences LLP(U.S.)
|
|
Market Opportunities
|
|
Market Definition
Coagulation Factor VII, also known as Factor VII or FVII, is a protein in the blood that plays a critical role in the coagulation (blood clotting) cascade, which is a complex series of events that helps to stop bleeding when blood vessels are injured. It is one of the many clotting factors involved in this process
Global Coagulation Factor VII Treatment Market Dynamics
Drivers
- Increasing Incidence of Hemophilia
Hemophilia is a rare genetic disorder characterized by the inability of the blood to clot properly. With advancements in diagnosis and awareness, there is a growing recognition of the disease, leading to an increased demand for factor VII treatment products.
- Expanding Hemophilia Market
The market for hemophilia and related bleeding disorders is expected to grow as the global population ages and the prevalence of these conditions increases. Emerging markets in developing countries are also contributing to market growth.
- Gene Therapy and Personalized Medicine
Gene therapy for hemophilia is a promising area of research. Innovative approaches such as gene editing and gene replacement therapies aim to provide long-term solutions for patients, potentially reducing the need for frequent factor VII treatment.
Opportunities
- Advancements in Therapeutics
The development of novel factor VII treatment options, including recombinant factor VIIa (rFVIIa) and plasma-derived factor VII concentrates, has expanded treatment choices for patients. Ongoing research and development efforts may lead to even more effective and convenient treatment options.
- Awareness and Education
Awareness campaigns and educational efforts targeting both healthcare professionals and patients can lead to earlier diagnosis and treatment of bleeding disorders, thus increasing the demand for factor VII treatment products.
Restraints/Challenges
- High Cost of Treatment
Factor VII replacement therapy can be expensive, especially for patients with severe bleeding disorders who require regular treatment. The high cost of these therapies can be a significant barrier to access for some patients and healthcare systems.
-
Limited Patient Pool
Coagulation factor VII treatment is primarily used for individuals with specific bleeding disorders, such as hemophilia with inhibitors or Factor VII deficiency. These conditions are relatively rare, which limits the size of the patient pool and potential market growth.
This global coagulation factor VII treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global coagulation factor VII treatment market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In February 2023, Sanofi announced that FDA approves once-weekly ALTUVIIIO, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
- In April 2020, LFB announces FDA approval of seven fact, a new recombinant coagulation factor VII a, for the treatment of adults and adolescents with hemophilia a or b with inhibitors
Global Coagulation Factor VII Treatment Market Scope
The global coagulation factor VII treatment market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Inherited Factor VII Deficiency
- Non-inherited Factor VII Deficiency
Treatment
- Recombinant Factor VIIa
- Fresh Frozen Plasma and Cryoprecipitate
- Prothrombin Complex Concentrates
- Antifibrinolytic Agents
- Others
Diagnosis
- Clotting Tests
- Factor Assays
- Prenatal Diagnosis
- Others
Symptoms
- Bleeding in Soft Tissues and Muscles
- Frequent Bruising
- Bleeding in the Spaces of Joints
- Excessive Bleeding from Injuries or Surgical Wounds
- Nosebleeds
- Blood in Urine
- Bleeding Gums
- Heavy Menstrual Bleeding
- Bleeding in the Skull
- Bleeding in the Gut
- Others
Dosage
- Tablet
- Injection
- Others
Route of Administration
- Oral
- Intravenous
- Others
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Coagulation Factor VII Treatment Market Regional Analysis/Insights
The global coagulation factor VII treatment market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global coagulation factor VII treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global coagulation factor VII treatment market because of the strong base of healthcare facilities, strong presence of major players in the market, rising demand of the coagulation factor VII treatment products and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Coagulation Factor VII Treatment Market Share Analysis
The global coagulation factor VII treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global coagulation factor VII treatment market.
Some of the major players operating in the global coagulation factor VII treatment market are:
- Pfizer Inc. (U.S.)
- Bayer AG (Germany)
- Baxter (U.S.)
- Biogen (U.S.)
- Octapharma AG (Switzerland)
- CSL Limited (Australia)
- Novo Nordisk A/S(Denmark)
- Mylan N.V. (U.S.)
- Sanofi (France)
- Zydus Cadila (India)
- Aurobindo Pharma (India)
- Takeda Pharmaceutical Company Limited (Japan)
- Akorn, Incorporated (U.S.)
- Xanodyne Pharmaceuticals, Inc. (U.S.)
- AmeriGen Life Sciences LLP (U.S.)
SKU-